Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDIAN: Vedolizumab vs adalimumab dose intensification in Crohn's disease with loss of response to first-line adalimumab
2023-508154-25-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Crohn's disease comparing Adalimumab dose intensification with Vedolizumab second-line (2 arms). Primary endpoint: Clinical and biomarker remission at week 24. Planned start Jan 2024; status: authorised.
02
Drugs
vedolizumabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-508154-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508154-25-00.